Protein-coding and non-coding RNA biomarkers for early detection of CLL

用于早期检测 CLL 的蛋白质编码和非编码 RNA 生物标志物

基本信息

  • 批准号:
    8629982
  • 负责人:
  • 金额:
    $ 57.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-06-01 至 2019-05-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in the Western hemisphere. Its clinical course is heterogeneous and difficult to predict; overall survival (OS) after diagnosis varies considerably (from <2 years to decades), making such predictions of utmost importance. Some patients diagnosed with Rai stage 0 (lymphocytosis of e5,000 B lymphocytes/¿L) or 1 (lymphocytosis with lymphadenopathy) never need treatment; others progress rapidly. Generally accepted guidelines recommend starting treatment only after disease progression (characterized by development of anemia, or lymphadenopathy, among other signs). We and others have shown that an intricate interplay between abnormalities in protein-coding genes (PCGs) and non-coding RNAs (ncRNAs) is causally involved in CLL initiation, and progression. We hypothesize that the risk of progression is related to intrinsic biologic characteristics (e.g. expression of PCG or ncRNA from malignant B cells as well as from viral origin) of the CLL clone that exists early in the disease course. Thus, it should be possible to distinguish patients who are at risk of progression from patients with indolent CLL (defined as stable Rai stage 0/I disease not requiring therapy for e5 years after diagnosis). Patients diagnosed with any stage of CLL, before or after treatment, may undergo a Richter's transformation (RT); they develop an aggressive diffuse large B-cell lymphoma that is typically therapy resistant and associated with short OS. About 80-90% of RT is clonally related to the CLL clone. We hypothesize that the risk to develop RT is associated with intrinsic biologic characteristics of the CLL clone before transformation. Thus, it should be possible to identify those patients who are at risk of RT early in the disease course. None of the present used clinical markers can do this with high accuracy. This proposal's goal is to focus on this challenging subset of clinically early stage cases to identify expression signatures of coding and non-coding RNA transcripts, elucidate their roles in disease progression, and their clinical significance as biomarkers of early diagnosis. Our long-term goal is to find interactor pairs of microRNAs and target PCGs with key roles in the onset of disease, understand their mechanisms of action, and use the acquired knowledge to develop new diagnostic and prognostic tools.
摘要 慢性淋巴细胞白血病(CLL)是西方国家成人中最常见的白血病。 半球其临床过程是异质性的,难以预测; 诊断差异很大(从<2年到几十年),使这种预测的最大 重要性一些患者被诊断为Rai 0期(淋巴细胞增多症e5,000 B淋巴细胞/L) 或1(淋巴细胞增多伴淋巴结病)不需要治疗;其他人进展迅速。一般 公认的指南建议仅在疾病进展后开始治疗(特征为 贫血或淋巴结病的发展,以及其他体征)。我们和其他人已经证明, 蛋白质编码基因(PCG)和非编码RNA异常之间的复杂相互作用 非编码RNA(ncRNA)与CLL的起始和进展有因果关系。我们假设 进展与内在生物学特征(例如PCG或ncRNA的表达)相关 来自恶性B细胞以及来自病毒来源)的CLL克隆,该克隆存在于 病程。因此,应该可以区分有进展风险的患者 来自惰性CLL患者(定义为不需要e5治疗的稳定Rai 0/I期疾病 诊断后10年)。在治疗前或治疗后诊断为任何阶段的CLL的患者, 经历里希特转化(RT);他们发展为侵袭性弥漫性大B细胞淋巴瘤 约80-90%的RT与克隆相关, CLL克隆我们假设发生RT的风险与内在的 转化前CLL克隆的生物学特性。因此,应该可以 在病程早期识别出那些有RT风险的患者。没有一件礼物是用过的 临床标记物可以以高准确度完成这一点。本提案的目标是关注这一点 具有挑战性的临床早期病例子集,以识别编码的表达特征 和非编码RNA转录本,阐明它们在疾病进展中的作用,以及它们的临床 作为早期诊断的生物标志物的意义。我们的长期目标是找到相互作用对, microRNA和靶向PCG在疾病发作中起关键作用,了解它们的机制, 行动,并利用所获得的知识开发新的诊断和预后工具。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LYNNE V. ABRUZZO其他文献

LYNNE V. ABRUZZO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LYNNE V. ABRUZZO', 18)}}的其他基金

Protein-coding and non-coding RNA biomarkers for early detection of CLL
用于早期检测 CLL 的蛋白质编码和非编码 RNA 生物标志物
  • 批准号:
    9277433
  • 财政年份:
    2014
  • 资助金额:
    $ 57.32万
  • 项目类别:
Protein-coding and non-coding RNA biomarkers for early detection of CLL
用于早期检测 CLL 的蛋白质编码和非编码 RNA 生物标志物
  • 批准号:
    8850833
  • 财政年份:
    2014
  • 资助金额:
    $ 57.32万
  • 项目类别:
Validation of RNA and DNA Biomarkers of Prognosis in Chronic Lymphocytic Leukemia
慢性淋巴细胞白血病预后的 RNA 和 DNA 生物标志物的验证
  • 批准号:
    7291634
  • 财政年份:
    2006
  • 资助金额:
    $ 57.32万
  • 项目类别:
Validation of RNA and DNA Biomarkers of Prognosis in Chronic Lymphocytic Leukemia
慢性淋巴细胞白血病预后的 RNA 和 DNA 生物标志物的验证
  • 批准号:
    7138943
  • 财政年份:
    2006
  • 资助金额:
    $ 57.32万
  • 项目类别:
Validation of RNA and DNA Biomarkers of Prognosis in Chronic Lymphocytic Leukemia
慢性淋巴细胞白血病预后的 RNA 和 DNA 生物标志物的验证
  • 批准号:
    7477702
  • 财政年份:
    2006
  • 资助金额:
    $ 57.32万
  • 项目类别:

相似海外基金

Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
  • 批准号:
    DP240100640
  • 财政年份:
    2024
  • 资助金额:
    $ 57.32万
  • 项目类别:
    Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
  • 批准号:
    23K01889
  • 财政年份:
    2023
  • 资助金额:
    $ 57.32万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
  • 批准号:
    10452217
  • 财政年份:
    2022
  • 资助金额:
    $ 57.32万
  • 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
  • 批准号:
    10670838
  • 财政年份:
    2022
  • 资助金额:
    $ 57.32万
  • 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
  • 批准号:
    DP200100492
  • 财政年份:
    2020
  • 资助金额:
    $ 57.32万
  • 项目类别:
    Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
  • 批准号:
    407264
  • 财政年份:
    2019
  • 资助金额:
    $ 57.32万
  • 项目类别:
    Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
  • 批准号:
    18K18240
  • 财政年份:
    2018
  • 资助金额:
    $ 57.32万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
  • 批准号:
    17K12379
  • 财政年份:
    2017
  • 资助金额:
    $ 57.32万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
  • 批准号:
    17K13937
  • 财政年份:
    2017
  • 资助金额:
    $ 57.32万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
  • 批准号:
    8742767
  • 财政年份:
    2014
  • 资助金额:
    $ 57.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了